ORBi: Zervosen Astrid - Development of new drugs for an old target

Reference : Development of new drugs for an old target — the penicillin binding proteins.


	Document type :	Scientific journals : Article
	Discipline(s) :	Life sciences : Biochemistry, biophysics & molecular biology Life sciences : Microbiology Human health sciences : Immunology & infectious disease
	To cite this reference:	http://hdl.handle.net/2268/134239

Title :	Development of new drugs for an old target — the penicillin binding proteins.
Language :	English
Author, co-author :	Zervosen, Astrid [Université de Liège - ULg > > Centre de recherches du cyclotron >]
	Sauvage, Eric [Université de Liège - ULg > > Centre d'ingénierie des protéines >]
	Frère, Jean-Marie [Université de Liège - ULg > > Centre d'ingénierie des protéines >]
	Charlier, Paulette [Université de Liège - ULg > Département des sciences de la vie > Cristallographie des macromolécules biologiques >]
	Luxen, André [Université de Liège - ULg > Département de chimie (sciences) > Chimie organique de synthèse >]
Publication date :	2012
Journal title :	Molecules
Volume :	17
Issue/season :	11
Pages :	12478-505
Peer reviewed :	Yes (verified by ORBi)
Audience :	International
e-ISSN :	1420-3049
Country :	Switzerland
Keywords :	[en] non-beta-lactam ; Penicillin Binding Protein
Abstract :	[en] The widespread use of β-lactam antibiotics has led to the worldwide appearance of drug-resistant strains. Bacteria have developed resistance to β-lactams by two main mechanisms: the production of β-lactamases, sometimes accompanied by a decrease of outer membrane permeability, and the production of low-affinity, drug resistant Penicillin Binding Proteins (PBPs). PBPs remain attractive targets for developing new antibiotic agents because they catalyse the last steps of the biosynthesis of peptidoglycan, which is unique to bacteria, and lies outside the cytoplasmic membrane. Here we summarize the “current state of the art” of non-β-lactam inhibitors of PBPs, which have being developed in an attempt to counter the emergence of β-lactam resistance. These molecules are not susceptible to hydrolysis by β-lactamases and thus present a real alternative to β-lactams. We present transition state analogs such as boronic acids, which can covalently bind to the active serine residue in the catalytic site. Molecules containing ring structures different from the β-lactam-ring like lactivicin are able to acylate the active serine residue. High throughput screening methods, in combination with virtual screening methods and structure based design, have allowed the development of new molecules. Some of these novel inhibitors are active against major pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and thus open avenues new for the discovery of novel antibiotics.
Research units :	Centre de Recherches du Cyclotron - CRC ; Centre d'Ingénierie des Protéines - CIP
Target :	Professionals ; Students ; Others
Permalink :	http://hdl.handle.net/2268/134239

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Restricted access	molecules-17-12478.pdf		Publisher postprint	450.05 kB	Request copy

All documents in ORBi are protected by a user license.

Dspace v1.5